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BACKGROUND: People living with HIV/AIDS have been stigmatized since the beginning of the 
epidemic leading to severe social consequences related to their rights, health care services, freedom, self-
identity and social interactions. Provision of antiretroviral drugs is believed to contribute in lessening the 
effect of stigma and discrimination in those who are enrolled in care and treatment. The objective of this 
study was to determine the level of stigma faced by people living with HIV/AIDS and to explore the effect 
of access to antiretroviral therapy on stigma against people living with HIV/AIDS.  
METHODS: A cross-sectional study was conducted from August 7 to September 1, 2007 in Jimma 
University Hospital antiretroviral therapy clinic. A sample of 270 patients attending the antiretroviral 
therapy during the study period was included in the study. An Amharic version of structured 
questionnaire containing a 40-point HIV stigma scale was to collect the data. Data were coded, entered 
in to a computer and analyzed using SPSS for windows 12.0.1. 
RESULTS: Of the total 270 respondents, 149 (55.2%) were on antiretroviral therapy while 121 (44.8%) 
were treatment naïve but were having follow up in the antiretroviral clinic based on the national 
antiretroviral therapy guideline. Females comprised 148 (54.2%) of the respondents. Majority of the 
respondents 208 (77.0%) were in the age group 25-49. The prevalence of actual stigma in people living 
with HIV/AIDS was low 45 (16.6%) when compared with the fear of being stigmatized (perceived 
stigma) which was195 (72.2%). The prevalence of disclosure concern and internalized stigma were 231 
(86.3%) and 232 (85.9%), respectively. However, 245(90.7%) of the respondents reported a favorable 
attitudinal change on stigma with access to antiretroviral treatment. There was a statistically significant 
association between duration of antiretroviral therapy and favorable effect of access to antiretroviral 
therapy on stigma reduction (p<0.005). 
CONCLUSION: This study revealed that the fear of being stigmatized in people living with HIV/AIDS 
is much higher than the actual stigma. Access to antiretroviral drugs has a stigma alleviating effect on 
people living with HIV/AIDS. Apart from pretest and posttest counseling, psychosocial support and 
follow-up for PLWHA has to be strengthened, as this would help them to cope up with the internalized 
and perceived stigmata, which were higher in this study.  




Human Immunodeficiency Virus/ Acquired 
Immunodeficiency Syndrome (HIV/AIDS) has 
become the most deadly epidemic disease in 
history. Around 40.3 million people are living 
with HIV/AIDS and of which two third are living 
in Sub-Saharan Africa (1). Ethiopia, being one of 
the highly affected countries, HIV/AIDS is the 
leading cause of morbidity and mortality (2-5). 
Many people living with HIV/AIDS (PLWHA) 
have a better quality life as the result of 
increasing availability of antiretroviral therapy 
(ART). Nevertheless, many patients in sub 
Saharan Africa the devastating physical effects 
have been replaced by psychological conditions 
including social isolation, condemnation of their  
 
 
family, friends and society indicating high level 
of stigma and discrimination) (6, 7). 
 Stigma is a common human reaction to 
disease throughout history. Many diseases have 
carried considerable stigma including leprosy, 
tuberculosis, mental illnesses and many sexually 
transmitted diseases (STDS). HIV/AIDS is only 
the latest disease to be stigmatized (8, 9). 
 Factors that contributed to stigma include 
the fact that HIV/AIDS is considered as an 
incurable disease and people are scared of 
contracting HIV (9, 10). Besides, PLWHA are 
often thought as being responsible for getting 
infected. Religious or moral beliefs lead some 
people to believe that having HIV/AIDS is the 
results moral fault such as promiscuity that is sin 
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 Stigma is of utmost concern because as it is 
both the cause and effect of secrecy and denial, 
which are major catalysts for fueling HIV 
pandemic. In some places although the advent of 
free and accessible ART has offered hope and 
encouraged people to go for testing, stigma 
remains a barrier to testing (11). Without testing, 
which is an essential first step to ART people who 
are infected remain transmitting the virus to 
others. When individuals seek for care, ART has 
lost much of its potential effectiveness as a 
prevention strategy (12, 13). 
 In many African societies, PLWHA and 
their family members visit traditional healers 
before seeking modern health care. In fact, some 
may not want to be seen near an organization 
working on HIV/AIDS for the fear of being 
stigmatized (7, 14). In areas of considerable 
poverty, expending resources on PLWHA may be 
thought as wasteful since they will die anyway 
(14). 
 Disclosing HIV sero-status can be a double-
edged sword. On the one hand, disclosure 
alleviates the stressful burden of concealment by 
providing emotional support from others, on the 
other disclosure exposes PLWHA to stigma and 
discrimination from others (15). Stigma, by any 
form creates an emotional burden that has a direct 
negative impact on disease progression in 
PLWHA and could also affect adherence to ART 
(14, 15). 
 Tackling stigma poses challenges, since it is 
often based in deeply entrenched social and 
cultural beliefs. Although stigma is not likely to 
be eradicated totally, it can be managed somehow 
(9, 10, 16) and cannot flourish when silence, 
shame, secrecy and denial are weakened or absent 
all together (17). 
  ART drugs have not only improved the life 
of PLWHA in terms of delaying disease 
progression and improving quality of life but also 
seem also to have an effect on stigma (18). The 
more accessible ART became, the more it is 
expected that people would feel to know their 
sero-status using voluntary counseling and testing 
(VCT) or provider initiated counseling and testing 
(PICHT) (19,20). ART has the capacity to 
transform HIV infection from an incurable “death 
sentence” into a treatable “chronic illness”, 
reducing the stigma of the disease and stimulating 
people’s willingness to be tested and disclose 
their sero-status (18,19,20). It has been 
documented that access to HAART was a 
powerful mechanism to reduce HIV related 
stigma (18).  
 There is paucity of information concerning 
the level of stigma and discrimination of PLWHA 
in sub-Saharan African countries including 
Ethiopia. In one study done in Jimma on the 
extent and determining factors for HIV\AIDS 
related stigma, 33.4% of those who had not been 
tested for HIV reported fear of  being 
discriminated by the public if they  were found  to 
be positive for HIV (21). 
Studies on HIV stigma so far assessed attitudes of 
the non-infected people about those who are 
infected to understand why HIV itself is so 
stigmatized. HIV stigmata in the context of ART 
have not been explored in previous researches. 
The increased access to ART in developing 
countries and its possible mitigating effects on 
stigma has been suggested as a topic of research 
priority by different authors (6, 7, 9, 10,16). 
Therefore, the objective of this study was to 
estimate the level of different types of stigma and 
discrimination faced by PLWHA attending ART 
clinic its association with access to ART. 
 
 MATERIALS AND METHODS 
 
This cross-sectional study was conducted from 
August 7th to September 1st, 2006 in Jimma 
University Specialized Hospital (JUSH) ART 
clinic, Jimma town. Jimma is located in Oromia 
region, 335 kms southwest of Addis Ababa. The 
ART clinic of JUH provides free ART drugs to 
eligible PLWHA. There is a regular follow up for 
all registered PLWHA attending the ART clinic 
and medical evaluation is done by one physician 
and four nurses who had a special training on 
ART and HIV care. One senior specialist is 
available for consultations. 
 A sample of 287 PLWHA were taken with 
by assuming estimated prevalence of stigma of 
50% , margin of sampling error tolerated to be 
0.05 at  95% confidence level. The final sample 
size was calculated using finite population 
correction. An estimate was made for the study 
period with the assumption that on average 15 
patients would come to the ART clinic.  A clinic 
based convenient sampling technique was 
employed where all PLWHA who happened to 
come to JUH, ART clinic during the study period 
were included in the study. Subjects with 
documented HIV positive sero-status in the ART 
clinic, age 18 years and above and willing to 
respond to the questionnaire with an informed 
consent were included in the study. 
 The variables collected include socio-
demographic characteristics; duration of sero-
positivity; duration of ART for those on treatment 
and duration of follow-up for those who were 
treatment naive; attitudinal effects of access to 
ART on stigma against PLWHA; and variables of 
stigma types: Internalized stigma, Perceived 
stigma, Actual stigma and Disclosure concerns.  
 A 40-point HIV-Stigma scale questionnaire 
was used to measure the level of stigma and 
discrimination felt by PLWHA. A structured 
questionnaire was used to assess if there were 
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attitudinal changes by access to ART on the 
stigma and discrimination. After adequate 
training on the objective of the study and data 
collection techniques, nurses working at JUH, 
ART clinic collected the data. The questionnaire 
was interpreted into Amharic language and 
retranslated back to English and standardized to 
have same meaning by all the data collectors. 
Pretest was done on 10 subjects before the data 
collection to check the reproducibility of the data 
collected and an ongoing supervision was made 
by the principal investigator during the data 
collection to ensure the quality of data.  
 The collected data were cleaned, coded, 
entered and analyzed using SPSS for windows 
12.0.1. Pearson’s Chi-square tests with Yates 
correction was performed whenever necessary. P 
values less than 0.05 were considered as 
statistically significant. 
A very reliable and valid 40-point HIV stigma 
psychometric assessment scale employed 
elsewhere was used (22,23). The 40-point HIV 
stigma scale with its subscales was calculated to 
quantify the types of stigma. A score of 0 was 
given for those who answered strongly disagree 
and disagree. A score of 1 was given for those 
who chose agree and strongly agree. The scores 
were summated and a total score greater or equal 
to 50% was considered as having a stigma. A 
total score less than 50% was considered as not 
having a stigma. 
 For the attitudinal effect of access to ART 
on stigma, similar scoring was used. Accordingly 
1 point was given for those who chose agree and 
0 point for those who chose neutral or disagree. 
The total scores were summated and score greater 
than or equal to 50% were considered to have 
favorable effect of access to ART on stigma while 
those who had a percentage score of less than 
50% were considered to have no favorable effect 
of ART on stigma. 
 The proposal was approved by the Student 
research program and permission was obtained 
from the medical director of JUSH. A verbal 
informed consent was obtained before 
interviewing each PLWHA. Confidentiality of the 
information collected from each respondent was 
ensured. The objective of the study was explained 
to the participants.  
The following operational definitions were used: 
Overall Stigma: any measure entailing distinction 
among persons depending on their confirmed or 
suspected HIV status. The overall 40 questions of 
the HIV stigma scale, includes the four types of 
stigmata. 
Actual stigma (personalized stigma): is the actual 
stigma that PLWHA experienced in a real event 
also called enacted stigma. 
 Disclosure concerns: factors that relate to 
PLWHA, their worries whether to disclose HIV 
status or keep it secret.  
 Negative self- image (internalized stigma): the 
internal feelings of shame and guilt because one 
has HIV.  
Perceived stigma (public attitude): the concern of 





A total of 270 PLWHA participated in the study 
from a sample size of 287 PLWHA with a 
response rate of 94%. The non- responses were a 
few PLWHA who were not willing to respond the 
interview.  
Among the 270 respondents, 122 (45.2%) were 
males and 148 (54.2%) females. Two hundred 
eight (77%) were in the age group of 25-49 and 
55 (20.4%) were less than 25 years of age and 
only 7 (2.6%) were the age group 50 years and 
above. Christians comprised 170 (63.0%), Oromo 
139 (51.5 %) and larger proportion 96 (35.5%) 
attended elementary and 97 (35.9%) for 
secondary education. One hundred fifty one (55.9 
%) were married and 73 (27%) were unemployed 
(Table 1). 
 The reason for knowing sero-status or first 
HIV diagnosis differed among the study 
participants. The vast majority of the respondents, 
183 (67.8%) knew their sero-status for the first 
time when they got sick, followed by VCT, which 
accounted   for 68 (25.2%). Of the total 
respondents, 149 (55.2%) were started on ART 
based on the national ART eligibility guideline 
and 121 (44.8%) were not started on ART but 
were having follow-up in ART clinic. For those 
on ART, a combination of 2 Nucleoside Reverse 
Transcriptase Inhibitors (NRTI) and 1 Non-
Nucleoside Reverse Transcriptase inhibitor 
(NNRTI) were the regimens that were 
administered as a HAART. With regards to 
overall stigma, 231 (85.6%) of the study 
population had been stigmatized, of which 126 
(46.7%) were females and 105 (38.9%) were 
males. Concerning the different types of stigma, 
45 (16.6%) of the total respondents experienced 
actual stigma, 195 (72.2%) a perceived stigma, 
233 (86.3%) had a disclosure concern and 232 
(85.9%) had an internalized stigma (Table 1). 
 Reason for knowing sero-status showed a 
statistically significant association with internal 
stigma, disclosure concern and overall stigmata of 
HIV/AIDS (P<0.05). In those who were on ART, 
actual stigma and overall stigma were higher than 
for those who were treatment naïve. In contrast, 
disclosure concern was shown to be significantly 
higher among treatment naïve cases than those 
taking ART (P<0.001) (Table1). 
 Of 149 cases on ART, 50(33.6%) had been 
taking ART for less than 6 months, 49 (32.9%) 
were taking for a period ranging 6 months to 1 
year and 21(14.1%) reported to had been taking 
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for more than 2 years. On the other hand, of 121 
treatment naïve cases 58 (47.9%) had follow up in 
the ART clinic for less than 6 months, 53 (43.8%) 
for 6 months –1 year and only 3 (2.5%) for 
greater the 2 years (Table 1). 
 One hundred forty four (53.3%) knew their 
sero-status in the 6month to 3-year period while 
89 (33.0 %) for less than six months and only 37 
(13.7%) knew since 3 years. There was a 
statistically significant (P < 0.005) association 
between duration of knowing sero-status and 
disclosure (Table 2). 
 
Table 1. Relation between socio-demographic and other characteristics with the different stigmata types in  
               PLWHA attending JUH, ART clinic, Jimma, South Western Ethiopia, August 2006. 
Socio demographic 
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           25-49 


























          Christian  
          Muslim  
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           Amhara  
           Gurage 
           Kaffa 






































   Illiterate 
   Read & write  
   Grade 1-6 
   Grade 7-12   






































     Single  
     Married           
     Divorced 































Occupational status  
    Unemployed  
    House wife 
    Self employed  
    Gov. employed  
    Farmer  
    Local trader  
    Students  























































Reason for Knowing 
sero-status  
Premarital  preparation       
Death/illness of partner 
Travel/visa 













































  Started on ART 



















    † Traditional beliefs and no religion                ¥ House renters  
∞ All other ethnicities and nationalities           § PLWHA on follow up but not started on ART 
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Table 2. Duration after knowing self sero-status knowledge verses disclosure concern in PLWHA  
               attending JUH, ART clinic, Jimma, South Western Ethiopia, August 2006. 
 
 
Duration after  knowing self 
sero-status 
Disclosure concern  
 






<6 months 6 (6.7) 83 (93.3) 89 (33.0)  
< 0.005 
 
6 month-3 year 19 (13.2) 125 (86.8) 144 (53.3) 
>3 years 12 (32.4) 25 (67.6) 37 (13.7) 
Total  37 (13.7) 233 (86.3) 270 (100)  
 
For the questions on stigma in the context of ART 
which were used to assess the attitude of PLWHA 
on stigma with access to ART, 268 (99.3%) of the 
study population agreed that they considered 
HIV/AIDS as a treatable disease. Most of the 
respondents 232 (85.9%) considered diseases from 
opportunistic infections such as chronic diarrhea; 
tuberculosis and paresis are treatable in HIV 
patients. The same proportion of the study 
participants agreed that they no more fear 
disclosing their sero-status since there is a treatment 
for HIV. However, 56 (20.7%) and 55 (20.4%) of 
the respondents said that they would feel ashamed 
of visiting ART clinic taking ART drugs, 
respectively (Table 3). 
 
Table 3.  Frequency distribution of responses to attitudinal questions on stigma and discrimination in  
                relation to ART in PLWHA attending JUH, ART clinic, Jimma, Southwestern Ethiopia, August  
                2006. 
 
Attitudinal questions on 







Because ART drugs are available, I consider HIV/AIDS as 








 I believe that ART drugs improve the health of PLWHA. 253 (93.7) 
 
16 (5.9) 1 (0.4) 
 
I consider disease like (TB, chronic diarrhea, paresis) could 









Because there is a treatment for HIV by ART drugs, I no 
more fear disclosing my status to friends or any other 












I have seen my friends, family members or persons I know 
have changed their negative views on me since I started 

















56 (20.7) 6 (2.2) 
 I do not feel ashamed or afraid to take ART drugs. 209 (77.4) 55 (20.4) 6 (2.2) 
 
The overall assessment of attitudinal effect of 
access to ART on the stigma reduction revealed 
that of the total respondents, 245 (90.7%) of the 
study participants reported favorable effect of ART 
on the stigma reduction while the rest 25 (9.3%) 
said unfavorable effect on stigma. Of the total 
respondents, 111 (41.1%) males and 134 (49.6%) 
of females reported a favorable effect of access to 
ART on stigma reduction. A  
 
statistically significant(P< 0.005,)  association was 
observed between duration of ART therapy and 
effect of access to ART on stigma, the longer the 
duration on ART , the more favorable effect ART 
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Table  4. Attitudinal  effect of  access to ART on stigma by sex, duration of treatment and duration after  
                knowing self sero-status in PLWHA attending JUH, ART clinic, Jimma, South Western Ethiopia,  





Effect of access to ART on stigma and discrimination  
 








   Male  











P > 0.05 
   Total 25 (9.3) 245 (90.7) 270 (100.0) 
Duration of ART     
   <6 months 
   6 month-1 year 
   1-2 year 

















P < 0.005 
 
 
    Total 25 (16.8) 124 (83.2) 149 (100.0) 
Duration after knowing sero-
status  
    <6 months 
    6 month-3 year 
    >3 years 
 
 














P > 0.05 
 




The study was based on a one-time interview that 
may not allow to fully explore the stigma and 
discrimination felt by PLWHA. The complexity of 
HIV related stigma and discrimination issues might 
also limit PLWHA from responding confidently to 
questions related personal experiences. Some of the 
questions on stigma could be subject to recall bias. 
A two year experience may not be adequate to 
determine the interventional outcome of access to 
ART on stigma which could not be captured from 
the current data as the Ethiopian experience with 
ART introduction has not yet reached five years. 
The study involved only those PLWHA attending 
the ART clinic of JUSH that came during the study 
period; those who did not come to ART clinic 
might have different characteristics. Nevertheless, it 
has tried to assess the magnitude of stigmata and 
discrimination faced by PLWHA using a standard 
HIV stigma scale (22,23). This study has also 
opened an eye for exploring the effects of access to 
ART on stigma and discrimination. 
HIV/AIDS has increasingly been not merely a 
medical problem but also a social problem. The 
social consequences of HIV/AIDS-stigma and 
discrimination have made the third phase of the 
epidemic (7, 8, 10, 12). The population of this study 
is believed to represent those who had challenged 
the effect of stigma and discrimination and have 
accessed the benefits of antiretroviral therapy. 
Although the prevalence of stigma among this 
population is expected to be lower than the others, 
its extent reported by this study is alarming. The 
overall stigma (85.6%) in PLWHA was higher 
probably because it comprised the four 
interdependent subscales of the HIV stigma types. 
However, such a result is indicative of the 
magnitude of stigma among PLWHA which calls 
for an effort to avert stigma and discrimination 
(9,10). 
 Regarding the different types of stigma, only 
16.6% of the total respondents had an actual stigma 
which is a discrimination that was experienced at 
some point in the real life of PLWHA. A study in 
India using the same stigma scale showed an actual 
stigma prevalence of 26% in PLWHA (23). Though 
the figures are comparable, the percentage of actual 
stigma in this study is quite low. This may be 
explained by the fact that actual stigma could be 
underreported since subjects were questioned to 
report real occasions where they had been 
stigmatized in their life which might make them 
uncomfortable. Partly it might also be due to failure 
to remember past events. 
 Treatment naïve individuals were found to 
have a statistically significant (p<0.05) prevalence 
of actual stigma and overall stigma compared to 
those on treatment. The difference could be 
attributed to the duration of exposure to such 
incidences. Those who were on treatment are 
expected to have been with the infection for longer 
time than treatment naïve individuals, thus may 
have a stigmatizing body appearance with AIDS 
defining illnesses. Side effects of NRTI’s 
(Stavudine) causing lipodystrophy or rashes 
resulting in disfigurement can also add further 
stigma (20). This point needs further explorations 
in future researches. 
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Perceived stigma is a public concern or fear by 
PLWHA that they would be stigmatized. In this 
study, 72.2% of the study population had a 
perceived stigma compared to the Indian report 
where the prevalence was 97 % (23). The 
difference in the magnitude could be due to cultural 
differences regarding the fear of being stigmatized. 
 The disclosure concern (86.3%) in this study 
is comparable with that of Indian study (85%) (23). 
When compared with those taking ART, disclosure 
concern was found to be significantly higher in 
treatment naïve follow-ups (P<0.001). This shows 
that PLWHA taking ART might be more confident 
with the therapy they are taking and are less 
concerned disclosing their sero-status. This is 
consistent with the finding of a statistically 
significant association observed between duration 
of sero-status and disclosure concern in this study. 
This implies that longer stay with the virus, they 
may feel less pressured to disclose their sero-status, 
get confidence with the ART and the follow up. 
This is in contrary to a study in Jimma Town where 
33.9% of the study subjects who did not know their 
sero-status reported not let any body know about 
their sero-status (21). There seems to be a higher 
disclosure concern in PLWHA than the general 
population indicating that disclosure concern is 
more of related to being HIV positive and personal 
experience of having HIV than merely being a 
personal choice by an individual.  
 The study showed a high percentage of 
internalized stigma (negative self image) compared 
to an Indian study (20). The disparity could be due 
to differences in living conditions, life style, 
cultural and social supports. In spite of this, the 
trends of the four types stigmata were comparable 
to the Indian study that used the same HIV stigma 
scale (23). 
 There were no statistically significant 
associations between many of the socio-
demographic characteristics PLWHA and different 
types of stigmata; except for educational status and 
the actual stigma. With the higher educational 
status, there was lesser actual stigma experienced 
by PLWHA. This could be due to the better living 
and working conditions and social support in those 
with higher educational status (P<0.05). 
 All the four types of stigmata were higher in 
females though there was no statistically significant 
association. Most of the PLWHA knew their sero-
status when they got sick implying that people are 
not using the VCT centers to know their sero-status. 
Because of this fact, overall stigma, disclosure 
concern, and internal stigma were significantly 
higher (p<0.05) than those whose reason for the 
first HIV diagnosis was sickness. This is 
substantiated by the fact that those who sought care 
when they were debilitated are likely to experience 
internal stigma and overall stigma. The number of 
people going to VCT could be more important than 
the other reasons of knowing sero-status since it 
is an indirect indicator of HIV related stigma 
reduction (19, 24). There seems to be a tendency 
that with a growing VCT services, people will go 
forward to know their HIV sero-status.  
 Of all patients who were on ART, more than 
two-third had been on treatment for one year or less 
which can be explained by the late introduction of 
free ART in our country. However, despite recent 
introduction, this study has shown that access to 
ART can have a stigma reduction effect. More than 
90% of the respondents had given a favorable 
response on stigma reduction with access to ART. 
There was also a statistical significant association 
between duration of ART and the favorable effect 
ART on stigma reduction (p<0.005) which is a very 
encouraging finding. With more duration of ART, 
the attitude of PLWHA, their relatives and friends 
towards the disease tends to change (18-20). 
 In conclusion, this study showed that the 
overall stigma felt by PLWHA was quite high. But 
the prevalence of actual stigma was very low when 
compared to other types of stigmata including 
disclosure concern, perceived stigma and 
internalized stigma. Since actual stigma is low 
compared to fear of being stigmatized, PLWHA 
should be encouraged to battle against their internal 
stigma and the fear that hold them from disclosing 
their sero-status.    
 Many of the disclosure concerns and stigmata 
felt by PLWHA could be ameliorated with access 
to ART and longer duration of treatment. Thus, in 
the long run, HIV/AIDS related stigma can be 
expected to decline as it has already become 
treatable. 
 Apart from pretest and posttest counseling, 
psychosocial support and follow-up for PLWHA 
has to be strengthened as this would help them to 
cope up with the internalized and perceived 
stigmata, which were higher in this study. 
Reinforcing the ways to provide continual 
psychosocial support and care for PLWHA will 
reduce stigma that results in worsening of the 
disease progression affecting drug adherence and 




First of all, we would like to thank Jimma 
University, Medical Sciences Faculty, for allowing 
us to conduct research on this topic. We are very 
grateful to all patients who have participated in the 
study for giving us information on this sensitive 
issue. Finally, we would like to extend our great 












1. UNAIDS/WHO. AIDS Epidemic update; Dec 
2005. 
2.  Ministry of Health, Disease Prevention and 
Control department. AIDS in Ethiopia: Fifth 
report, MoH, 2005. 
3. Hladik W, Ismael S, Jelaludin A, Woledu A, 
Messele T, Wuhib T.  HIV/AIDS in    Ethiopia: 
Where is the epidemic heading? Sexually 
Transmitted Infections, 2006;    82:32-35. 
4. WHO/UNAIDS. Progress on Global Access to 
HIV Antiretroviral therapy: A   report on “3 by 
5” and beyond, March 2006. 
5.  Abate S.  Ethiopia’s free ART eligibility 
criteria revised: Press release, MOH October 
2005. 
6. Backstroke O. Curing stigma-the limit of 
antiretroviral access. New Eng J Med,   2005; 
53:753. 
7. Rankin W, Brennan S, Schell E, Rankin S. 
HIV/AIDS related stigma in Africa, A    call 
for community: Two papers on HIV and AIDS 
related stigma in Africa. San Francisco (CA), 
USA: Global AIDS Interfaith Alliance 
(GAIA), 2005: 32. 
8.  Mann J. AIDS-A global perspective. West J 
Med, 1987: 47-673. 
9.  Brown L, Trujillo L, Macintyre K. 
Interventions to reduce HIV/AIDS stigma:      
What we have learned?  AIDS Educ Prev, 
2003; 15(1):49-69. 
10.  Mawar N, Sahay S, Pandit A, Mahajan U. The 
Third phase HIV pandemic: Social 
consequences of HIV/AIDS stigma & 
discrimination & future needs. Indian J Med 
Research, 2005; 122: 471-484. 
11. Fredriksson J, Kanabas A. Avert HIV and 
AIDS stigma and discrimination. 2006. 
Available on: http://avert.org/aidsstigma.html, 
accessed on 20/11/2006. 
12. Rankin W, Brennan S, Schell E, Laviwa J. 
Rankin S. The stigma of being HIV       
positive in Africa. PLOS Med, 2005; 2(8):e247. 
13. Etiebet MA, Fransman D, Forsyth B, Coetzee 
N, Hussey G. Integrating       Prevention of 
mother to child HIV transmission into 
Antenatal Care: Learning from experiences of 
women in South Africa. AIDS Care, 2004; 
16:37-46. 
14.  Nyblade L, Pande R, Mathur S, MacQuarrie 
K, Kidel R. Disentangling HIV and  AIDS 
stigma in Ethiopia, Tanzania and Zambia. 
Washington DC, USA: International Center for 
Research on Women (ICRW), 2003:53. 
15. Peretti-Watel P, Spire B, Pierret J, Lert F, 
Obadia Y, The Vespa Group.      Management 
of HIV-related stigma and adherence to 
HAART: Evidence from a large Representative 
sample of outpatients attending French 
hospitals (ANRS-EN12- VESPA 2003). AIDS 
care, 2006; 18(3): 254-261. 
16. Parker R, Aggleton P. HIV and AIDS related 
stigma and discrimination: A conceptual 
framework and implications for action. Social 
Sciences Med, 2003;      57:13-24. 
17. Hogle JA. What happened in Uganda? 
Declining HIV prevalence, behavior change    
and the national response. Washington DC, 
USA. The Synergic Project, 2002:133. 
18. Ernesto C, Barrero A, Castro A. Experiences of 
stigma and access to HAART in      children 
and adolescents living with HIV/AIDS in 
Brazil. Social Sciences and      Medicine, 2006; 
62:1210-1228. 
19. Levy C, Miksad A, Fein T. From treatment to 
prevention: the interplay between HIV/AIDS 
treatment availability and HIV/AIDS 
prevention programming in Khayelitsha, South 
Africa. Journal of Urban Health: Bulletin of 
the New York Academy of Med, 2005; 82 (3): 
498-509. 
20. Ritzenthaler R. Delivering antiretroviral 
therapy in resource-constrained Settings: 
Lessons from Ghana, Kenya and Rwanda. 
Family Health International.2006 Apr 
10. Available from: 
http://www.fhi.org/en/HIVAIDS/pub/Deliverin
g+ART.htm., accessed on 20/11/06. 
21. Shiferaw Y, Girma B, Ayele B. Assessment of 
type, extent and determinant factor       for 
HIV/ AIDS related stigma & discrimination in 
Jimma town, Ethiopia; Ethiop J Health Sci. 
2004; 14: 1-11. 
22. Berger B, Estuing C. Lashley RF. Measuring 
stigma in people with HIV:      Psychometric 
assessment of the HIV stigma scale. Research 
in Nursing & Health, 2001; 24:518-529. 
23.   Thmas BE, Rehman F, Suryanarayanan O,  
        Josephine K, Dilip M, Dorairaj V,        
        Swaminathan S. How stigmatizing is stigma in  
        the life of people living with HIV: A study on  
        HIV positive individuals from Chennai, South  
        India. AIDS Care, 2005; 17(7): 795-801. 
24.  Kalichman S, Simbayi L. HIV testing attitudes,  
       AIDS stigma, and voluntary HIV counselling  
       and testing in a black township in Cape Town,  
       South Africa . Sex Transm Infect, 2003;      
       79:442-447. 
